LXS196 is a selective inhibitor of the mitogen-activated protein kinase (MEK) pathway, specifically targeting MEK1 and MEK2 enzymes. It is primarily investigated for its potential in treating cancers driven by mutations in the RAS/RAF/MEK/ERK signaling cascade. Notably, LXS196 has shown promise in preclinical and clinical studies for the treatment of advanced or metastatic uveal melanoma, a rare form of melanoma that often harbors GNAQ or GNA11 mutations leading to MEK pathway activation. The compound is being evaluated in clinical trials, either as a monotherapy or in combination with other agents such as PKC inhibitors or immune checkpoint inhibitors, to enhance antitumor efficacy. Its ability to penetrate the blood-brain barrier also makes it a candidate for treating melanoma with central nervous system involvement. Due to its targeted mechanism, LXS196 offers a therapeutic strategy for patients with limited treatment options, particularly those with tumors resistant to conventional therapies.